Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3488954 | 1.00 | MAPT (0.36) | MAPTKMT2AMAPK1NPC1L3MBTL1 | |
| SCHEMBL3488951 | 0.92 | MAPT (0.35) | MAPTKMT2AMAPK1NPC1L3MBTL1 | |
| SCHEMBL638386 | 0.92 | MAPT (0.35) | MAPTKMT2AMAPK1NPC1L3MBTL1 | |
| SCHEMBL9662398 | 0.91 | MAPT (0.36) | MAPTKMT2AMAPK1NPC1L3MBTL1 | |
| SCHEMBL15850674 | 0.91 | MAPT (0.34) | MAPTKMT2AMAPK1NPC1L3MBTL1 | |
| SCHEMBL637947 | 0.90 | MAPT (0.34) | MAPTKMT2AMAPK1NPC1L3MBTL1 | |
| SCHEMBL636419 | 0.89 | MAPT (0.33) | MAPTKMT2AMAPK1NPC1L3MBTL1 | |
| SCHEMBL3490573 | 0.89 | MAPT (0.33) | MAPTKMT2AMAPK1NPC1L3MBTL1 | |
| SCHEMBL3491675 | 0.88 | MAPT (0.33) | MAPTKMT2AMAPK1 | |
| SCHEMBL636420 | 0.87 | FFAR4 (0.34) | MAPTKMT2AMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2498605-B1 | DIURETICS | MERCK SHARP & DOHME (US) | 2014-08-27 | — | — | EP | claimed |
| EP-2485734-B1 | DIURETICS | MERCK SHARP & DOHME (US) | 2014-07-02 | — | — | EP | claimed |
| EP-2326652-B1 | NITRO DERIVATIVES OF FURASEMIDE AND THEIR USE AS DIURETICS | MERCK SHARP & DOHME (US) | 2014-04-16 | — | — | EP | claimed |
| US-8354394-B2 | Diuretics | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | claimed |
| EP-2498605-A1 | DIURETICS | Merck Sharp & Dohme Corp. (US) | 2012-09-19 | — | — | EP | claimed |
| US-20120208838-A1 | DIURETICS | MERCK SHARP & DOHME LLC | 2012-08-16 | — | — | US | claimed |
| US-20120202845-A1 | DIURETICS | MERCK SHARP & DOHME LLC | 2012-08-09 | — | — | US | claimed |
| US-20100029678-A1 | DIURETICS | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | claimed |
| EP-2498605-B1 | DIURETICS | MERCK SHARP & DOHME (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2485734-B1 | DIURETICS | MERCK SHARP & DOHME (US) | 2014-07-02 | — | — | EP | disclosed |
| EP-2326652-B1 | NITRO DERIVATIVES OF FURASEMIDE AND THEIR USE AS DIURETICS | MERCK SHARP & DOHME (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8377911-B2 | Diuretics | MERCK SHARP & DOHME CORP. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8354394-B2 | Diuretics | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2498605-A1 | DIURETICS | Merck Sharp & Dohme Corp. (US) | 2012-09-19 | — | — | EP | disclosed |
| US-8119806-B2 | Cicletanine derivatives | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119806-B2 | Cicletanine derivatives | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| WO-2011043914-A1 | DIURETICS | MERCK SHARP & DOHME CORP. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2010014516-A1 | NITRO DERIVATIVES OF FURASEMIDE AND THEIR USE AS DIURETICS | MERCK & CO., INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029678-A1 | DIURETICS | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | disclosed |
| US-20100029678-A1 | DIURETICS | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029678-A1 | DIURETICS | NR3C2, REN, NR3C1 | MAPT 4222/4885KMT2A 1778/4885MAPK1 1494/4885 |
| US-20120202845-A1 | DIURETICS | REN, SLC5A1, AGTR1 | MAPT 2720/4885KMT2A 3818/4885MAPK1 1115/4885 |
| US-20120208838-A1 | DIURETICS | REN, AGTR1, AGTR2 | MAPT 2882/4885KMT2A 3480/4885MAPK1 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.